Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs DNLI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–5 Matrix Metrics)

ARVN Overall Winner 6-Pillar Tally: ARVN 5 – 0 DNLI (1 Tie) Matrix Metrics: ARVN 5 – 5 DNLI

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Denali Therapeutics Inc. (DNLI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.78 (17.9x Forward P/E, -10.1% operating margin), whereas DNLI carries 55.5/100 (HOLD) at $18.33 (N/M Forward P/E, -2481.1% operating margin).

  • Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. ARVN 52.9/100 HOLD), ARVN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-10.1% vs. -2481.1% operating margin) and revenue trajectory (-98.8% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs DNLI
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.78
-0.59% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
DNLI NASDAQ
Denali Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.33
-2.19% 1D
Market Cap $3.0B
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.36β · 48% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.3%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $19.25 · SMA50: $19.70

6-Pillar Scorecard Institutional Category Breakdown (ARVN 5 – 0 DNLI)

Columns: Metric · ARVN · DNLI
1. Valuation Multiples ARVN
Forward P/E 17.9x N/M
Trailing P/E 17.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x 138.2x
2. Growth & Scale ARVN
Revenue Growth (YoY) -98.8% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $275M $21M
Market Cap $449.9M $3.0B
3. Profitability & Quality ARVN
Gross Margin 96.7% N/A
Operating Margin -10.1% -2481.1%
Net Profit Margin -3.5% 0.0%
Return on Equity (ROE) -1.8% -33.9%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$160M -$486M
Cash Flow Margin -58.0% N/A
Net Cash / Leverage $81M Net Cash $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARVN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 108.7% (25th %ile) 78.2% (27th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 6.21x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (5) vs DNLI (5)
Institutional Metric ARVN DNLI Criterion Row Edge
Market Capitalization
Scale
$449.9M $3.0B Larger Scale DNLI
Trailing P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-98.8% -100.0% Higher Growth ARVN
Operating Margin (TTM)
Profitability
-10.1% -2481.1% Higher Margin ARVN
Net Profit Margin
Profitability
-3.5% 0.0% Higher Margin DNLI
Return on Equity (ROE)
Capital Efficiency
-1.8% -33.9% Higher ROE ARVN
52-Week Range Position
Momentum
6% ($6–$15) 25% ($15–$27) Stronger Trend DNLI
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 1.36β · 48% Vol Lower Realized Risk DNLI
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite DNLI
Trailing 12M Revenue (USD)
Operating Scale
$275M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 138.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$486M ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNLI +6.82 pp
ARVN: -2.73% · DNLI: +4.09%
3M Horizon DNLI +2.18 pp
ARVN: -26.78% · DNLI: -24.6%
6M Horizon DNLI +22.4 pp
ARVN: -22.78% · DNLI: -0.38%
1Y Horizon DNLI +39.88 pp
ARVN: -33.0% · DNLI: +6.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARVN Revenue DNLI Revenue ARVN Op. Margin DNLI Op. Margin Margin Leader
FY2018 $10M $130M -306.3% -35.9% DNLI
FY2019 $20M $30M -281.4% -810.0% ARVN
FY2020 $20M $340M -554.1% 18.7% DNLI
FY2021 $50M $50M -403.4% -607.8% ARVN
FY2022 $130M $110M -200.3% -324.3% ARVN
FY2023 $80M $330M -511.5% -59.5% DNLI
FY2024 $260M N/A -95.0% N/A ARVN
FY2025 $260M N/A -45.1% N/A ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNLI BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 78.2%
IV Percentile 27th %ile
Put/Call OI Skew 6.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact DNLI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DNLI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -2481.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs DNLI Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Denali Therapeutics Inc. (DNLI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.78 (17.9x Forward P/E, -10.1% operating margin), whereas DNLI carries 55.5/100 (HOLD) at $18.33 (N/M Forward P/E, -2481.1% operating margin). Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. ARVN 52.9/100 HOLD), ARVN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-10.1% vs. -2481.1% operating margin) and revenue trajectory (-98.8% vs. -100.0% YoY). Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with DNLI at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (N/A gross margin, -2481.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while DNLI shifted +153.8%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNLI.

ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas DNLI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 138.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus DNLI (-33.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, DNLI carries 78.2% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 6.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.